PharmaEssentia has submitted Premarket Application for P1101 with Polycythemia vera (PV) to FDA, a visit from the authority expected in August, according to the company. The company will have seven years of Orphan Drug Exclusivity (ODE) once it has the FDA approval.
The video clip on BBC starts with a patient sharing her journey through the diagnosis of rare blood disease to acceptance of commpassionate drug use that helps her regain the control of her life.
Through the real-life stories presented on BBC StoryWorks, the new drug are being brought to an international platform, bringing hope to MPN patients in every corner of the world.
As part of the StoryWorks series launched on 16 June to coincide with the world's largest biotech event, BIO Digital 2021, the story telling invites participation from world-leading pharmaceutical companies, including Samsung Biologics, Sanofi, Roche and Beigene. Through the life stories of patients and the introduction of professional doctors, PharmaEssentia demonstrates the strength in research and development Taiwan has, and provides an opportunity for treating rare diseases.